

A review on Management of Obesity

Abstract:

Obesity is one of the most challenging conditions that primary care physicians face in their profession. Despite the efforts of both patients and professionals, the condition is becoming more common. A multimodal strategy that includes food, physical exercise, and behavioral disorders is required for treatment. Drugs and surgery are also performed to receive desired results. This study summarises the data for each strategy, discusses how primary care physicians might best assist obese patients, and offers weight-loss advice.

New weight-loss techniques to treat obesity appear to have a bright future. Current medications have had limited weight reduction impacts in the overall obese population, but customized medicine will substantially impact smaller homogenous subpopulations of obese people. Multiple, complementary route drug combinations can produce double-digit weight loss in a larger, varied patient group. Furthermore, the advancement of sophisticated subcutaneous delivery technologies has paved the way for the creation of ground-breaking peptide and biologic medicines to treat obesity.

Obesity is a chronic condition that needs lifetime therapy. The BMI, waist circumference, and other risk variables are all measured in the obesity evaluation process. Diet and exercise should be part of the management plan. Only sibutramine and orlistat are FDA-approved for long-term usage so that they can be administered to selected individuals. The only alternative that produces persistent and considerable weight loss is bariatric surgery, provided to very obese individuals.

Keywords: obesity, combination therapy, bariatric therapy, exercise

INTRODUCTION :

Obesity is a fast-spreading epidemic that raises the risk of illness and mortality worldwide. Obesity is thought to be responsible for up to 300,000 fatalities each year in the United States; however, this statistic is debatable.

The project aims to conduct a comprehensive assessment of the existing evidence for obesity weight reduction therapies (lifestyle, surgical, and pharmaceutical) in people over 60, adolescents, and children.

Obesity has reached pandemic proportions in the United States. Recognizing obesity as a chronic disease allows for a better understanding of its management. The National Institutes of Health Consensus Conference on Gastrointestinal Surgery for Severe Obesity provides a paradigm for managing the highly obese, including medicinal versus surgical advice based on scientific and outcome data. Primary prevention, nutritional intervention, increased physical activity, behaviour change, and medication are all medical therapies for obesity. Obesity surgery is better known as Metabolic Surgery because it is based on the significant neural-hormonal effects of weight loss surgery on metabolism. Surgery involves a complete preoperative examination, risk assessment, and counseling in addition to the surgery itself. (1)

Discussion:

Diets:

A decrease in calorie consumption is required for long-term weight loss and maintenance. On the other hand, diets are useless in the long run without behavior adjustment and ongoing assistance from health specialists. Counseling patients on how to change their behavior can help reduce fat and calorie consumption. (1)

Drugs:

Until further proof of safety is available, physicians should avoid prescribing medicines that guarantee weight loss for longer than the FDA proved. This decision takes place on whether the patient will be motivated to make commitments for long-term diets and exercise changes in his daily lifestyle to lose weight and get into shape.

Appetite Suppressants:

Topiramate and rimonabant have been linked to weight reduction, although the FDA has not yet authorized them for this use.

In a meta-analysis (24-week data from many trials given in abstract form), topiramate, which modifies -aminobutyric acid receptors, was linked to a 6% weight reduction, but it was also linked to a high incidence of unfavorable central nervous system effects (especially paresthesias and loss of taste).

Rimonabant is a cannabinoid-1 receptor blocker that has not yet been licensed for usage in the US. Two extensive randomized studies have shown success, with one-year weight loss of 6-kg. The stated weight reduction may be optimistic because both studies had many dropouts. The rate of mental issues (depression and anxiety) was much more significant (almost double) in the rimonabant group than in the placebo group, a result that merits additional examination. (1)

Impairing mechanism of energy absorption:

From the ingested lipids, Orlistat prevents absorption of a fraction of energy. The FDA has authorized orlistat for two years of usage, but insurance may not be able to reimburse it. It's great for people who have diabetes, can handle a low-fat diet, and are at risk of getting the disease. Diarrhea and greasy stools are frequent gastrointestinal side effects, although they usually go away with time.

Combination Therapy:

There has been insufficient research on combining different weight-loss medicines; therefore, it cannot be suggested at this time. Incretins are hormones secreted after eating and help the pancreatic beta cells secrete more insulin. Many of these hormones have central effects that suppress appetite, and some of them (such as GLP-1) are effective in treating obesity. (1)

Endoscopic enhancement of effects of RYGB when weight regain occurs.

Weight gain or plateau in RYGB patients may be linked to an increase in the gastric pouch size or the outlet that is the Roux jejunal limb's anastomosis. The processes behind the rise in the size of the gastric pouch are unknown; hence, the change in the gastric pouch might be a cause or, perhaps, a result of excessive postprandial food consumption. On the other hand, endoscopic suturing, such as purse-string suturing or sclerotherapy, can shrink the outlet and restore weight loss. (2)

SURGERY:

Although bariatric surgery people have grown significantly, the operation may still be underutilized. Surgery has not been shown to reduce mortality, and there are no long-term randomized trials to answer this topic. The most frequent metabolic surgical treatments are Roux-en-Y gastric bypass, adjustable gastric bands, sleeve gastrectomy, and biliopancreatic diversion. Preoperative diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea were cured or improved in more than half of the patients. (3)

Exercise:

There is a lack of evidence from randomized studies to support the relevance of exercise in weight management. On the other hand, observational studies are essential and critical.

Many studies from different perspectives have concluded that healthy workouts in all ages and genders are linked to less weight gain over the years. (1)

Non-exercise Activity Thermogenesis:

Contribution to energy expenditure (NEAT) is by resting metabolic rate, the warmth of the food, and activity thermogenesis, classified into formal exercise and thermogenesis by nonexercise activity. NEAT refers to all energy expenditure except sleeping, eating, and organized exercise. Over the last century, the massive fall in NEAT has coincided with an equally significant rise in obesity. (1)

Facilitating behavior change:

Performing challenging cognitive activities, coping with tough emotional circumstances, and repressing thoughts and emotions make it more challenging to resist temptation a second time. Exercise and sleep improve self-control; thus, the link between obesity and chronic sleep deprivation is not surprising. Instead of the thought of resisting oneself from temptation as a fact of willpower, it should be seen as an obstacle to getting control of where a person's attention is focused.

Obesity behavioral treatment refers to a collection of ideas and approaches aimed at assisting overweight people in changing their maladaptive eating and exercise behaviors. The components of this strategy are described in this article and the short- and long-term outcomes of therapy and the use of behavioral and pharmacologic treatments in combination. It finishes with a review of options for improving obesity treatment in primary care. The effectiveness of behavioral and pharmacologic interventions is assessed in light of the new obesity management goals, which are to assist overweight people in achieving a healthful weight rather than an ideal one. Weight decreases of 5% to 10% of baseline weight are typically enough to ameliorate weight-related problems such as hypertension, type II diabetes, and dyslipidemia, according to an increasing body of evidence. It is not required to lose weight to gain these benefits, and it is not achievable for most severely obese

people. A new objective of behavioral treatment, which will be explored later, is to assist obese people in accepting smaller weight decreases.
(4)

Self-monitoring:

Self-monitoring of behaviour is a crucial part of behavior change. Several studies have shown that patients who closely control their calorie intake lose a lot of weight. People who keep track of their calorie intake have shown to be 10 kgs fitter and better shape than those who don't. Time-efficient self-monitoring to help with weight reduction is made easy with programs for portable devices, which have a feature of calculating calories, steps, etc. (5)

Treatment of obesity in older persons:

There were a total of 256 lifestyle intervention papers discovered, with 69 studies satisfying the criteria. After discovering no qualifying trials for medication or bariatric surgery, the search was widened to include non-randomized research. The research includes four medication trials and 66 surgical studies. A lifestyle intervention's weight reduction efficacy was comparable in older and younger people, with beneficial effects on various critical outcomes, including physical function and cardiovascular indicators. There was a scarcity of data on obesity medications in the elderly. Bariatric surgery data show comparable weight reduction and type 2 diabetes resolution in older adults compared to younger people, with the Same or little increased complication rates. Obesity surgery or significant lifestyle changes should not be considered contraindicated solely because of one's age. There is little evidence to support clinical judgments about obesity treatment in the elderly. (6)

The obese, functionally frail older adult has emerged as a new phenotype of frailty due to the increasing incidence of obesity in older populations worldwide. The convergence of the obesity pandemic and global greying will increase this concern's frequency. Due to age-related physiologic changes and a lack of consensus on specific criteria and cutoffs, there is uncertainty about the appropriate amount of obesity that should provoke an intervention. Obesity interventions for this group have also been limited due to concerns about adverse effects on lean mass, bone mineral density, and perhaps mortality. (7)

Diet-based Interventions:

Several trials have looked at and proven the benefits of exertion and working out as a significant aspect of reducing obesity. Mainly, all weight loss studies in this aspect include exercise and calorie deficit. one of these alone is not as effective as it may be slower to show changes. (7)

Calorie-restricted weight-loss diets :

In calorie-restricted diet vs. exercise research, calorie-restricted diets almost invariably showed more significant weight loss than activity-only therapies . As indicated in Research, exercise regimens with no strict diet will not show promising results, whereas a calorie-deficit diet produces average baseline body weight lowerings of five percent to 10 percent. It has several other sound effects: Studies found that an exercise program combined with an effective weights reduction diet plan was much more effective at decreasing body fat storage with improving cardio metabolism with its predisposing risk factors to obesity-related diseases recently done studies. (7)

Higher-protein weight-loss diets:

It is in agreement that the proteins needed of aged persons surpass the RDA of 0.8 g protein kg body weight¹ d¹, with intakes of 1.5 g protein kg body weight¹ d¹ or higher recommended in high-risk settings. Protein taking above the RDA is associated with improved lean mass reservation; the benefits of high-quality (animal) protein for appendicular lean mass retention, grip strength preservation, and a decreased risk of long-term function deterioration have been verified by recent data Framingham trial. There's increased resistance to supposed stimulation due to anabolic processes with age. Although with significant research, there is a conclusion that increased protein intake counteracts the decreased sensitivity to anabolic stimulation of aged muscles. Essential long-chain proteins, particularly leucine, activate the mTOR signaling system and increase proteins synthesizing in muscles, as shown in multiple short-term studies. For optimum protein synthesis in aged muscle, these studies advocate a balancing; ample protein takes during the whole day. The so-called "muscle full" phenomenon occurs when proteins being synthesized in muscles induced by amino acid inflow can't be activated again; hence balanced protein consumption, compared to consuming all the proteins in the evening meal, has been linked to improved outcomes. (7)

Weight-loss diets with other nutrient modifications:

Vitamin D deficiency has been linked to decreased muscle mass and strength, impaired balance, gait, and a higher risk of falling. Several investigations show the workings of vitamin D in obese menopause women with low serum 25-hydroxyvitamin D levels. Both groups participated in mild to heavy exercise. There was no diet alone arm in any of the studies conducted. Vitamin D is the second-most-studied nutrient in terms of function, after protein..(7)

Treatment of childhood obesity:

Lifestyle changes, medicines, and bariatric surgery are the three main treatment options. Recent research backs up the effectiveness of lifestyle treatments in the short term, demonstrating that persistent behavioral intervention improves the possibility of a long-term effect lasting up to two years. The latest research and regulatory choices on obesity drugs (such as orlistat, sibutramine, and metformin) are presented. New evidence suggests that bariatric surgery can lead to tremendous mass loss in obese teens, but it can also negatively affect them. An expert panel has released guidelines that change the way people think about increasing weight and provide a ground for dealing with it. All recommendations are compared to others, and they are given as a whole.

While primary prevention of childhood obesity is critical, there are currently no widely effective techniques available. An emphasis on treatment is incredibly crucial, given the enormous number of children with increased weight and their risks. A tiered approach is recommended, emphasizing early intervention and lifestyle improvements. (8)

Treatment of adolescent overweight and obesity:

Adolescence is a sensitive time for obesity to develop, and adolescent weight strongly correlates with adult weight. Previous studies of treatment options neglected to distinguish between teenagers and children, ignoring the population's specific characteristics.

Obesity may be improved in the near term with physical excursion and diet plans. Obesity therapies, on the other hand, have a more significant effect when used together than their use alone. Psychological therapies, like therapies to test behaviors and cognition, have shown great scope in making the essential life modifications for weight improvement; so longer-scoped researc and studies are required. Appraising the literature had several drawbacks. Comparisons between research are challenging due to variables and different definitions of obesity. Many researchers have failed to employ the amount of adipose in the body in the pubertal age to assess pubertal status, or to use exclusively teenage specimens. Despite these limitations, we conclude that current data suggests that therapies with behavioral and cognition-related treatments with food plus

physical exercising approaches may help reduce teenage fat; however, longer-term research and data are needed. (9-15)

CONCLUSION:

There should be a combination of more than one weight-loss tactic for a successful result and not only using one individually. Many of the methods covered in this research culminate in the LEARN program; it's a self help approach made for use in health care settings that will help get the patients started on the correct path. Consistent physical activity, the creation of relapse prevention techniques, regular follow-ups with their doctors, and support socially and emotionally from their close ones these all help predict maintaining weight; according to behavioral studies, all weight strategies overlap.

As stated before, physical exercise and workout are the strongest predictors in maintaining weight. Patients must follow a systematic workout routine and implement NEAT-increasing methods. Identifying relapse triggers and establishing strategies for dealing with them are critical abilities. When dieters believe they have consumed too much energy for the day, they are more likely to relapse. According to studies, this frequently leads to emotional eating and significant increases in energy intake. Patients should be warned not to let a single error set off a chain reaction of errors. Excessive alcohol drinking lowers one's ability to resist temptation and is a common cause of failure. In high-risk eating scenarios, patients should be counseled to avoid alcohol.

REFERENCES:

1. Kissane NA, Pratt JS. Medical and surgical treatment of obesity. *Best Pract Res Clin Anaesthesiol.* 2011;25(1):11-25. doi:10.1016/j.bpa.2011.01.001
2. Camilleri M, Acosta A. Combination Therapies for Obesity. *MetabSyndrRelatDisord.* 2018;16(8):390-394. doi:10.1089/met.2018.0075
3. Kissane NA, Pratt JS. Medical and surgical treatment of obesity. *Best Pract ResClinAnaesthesiol.* 2011;25(1):11-25. doi:10.1016/j.bpa.2011.01.001
4. GggWadden TA, Foster GD. Behavioral treatment of obesity. *Med Clin North Am.* 2000;84(2):441-vii. doi:10.1016/s0025-7125(05)70230-3
5. Thompson WG, Cook DA, Clark MM, Bardia A, Levine JA. Treatment of obesity. *Mayo ClinProc.* 2007;82(1):93-102. doi:10.4065/82.1.93
6. Haywood C, Sumithran P. Treatment of obesity in the older persons-A systematic review. *Obes Rev.* 2019;20(4):588-598. doi:10.1111/obr.12815
7. Bales CW, Porter Starr KN. Obesity Interventions for Older Adults: Diet as a Determinant of Physical Function. *Adv Nutr.* 2018;9(2):151-159. doi:10.1093/advances/nmx016
8. Uli N, Sundararajan S, Cuttler L. Treatment of childhood obesity. *Curr Opin Endocrinol Diabetes Obes.* 2008;15(1):37-47. doi:10.1097/MED.0b013e3282f41d6a
9. Tsiros MD, Sinn N, Coates AM, Howe PR, Buckley JD. Treatment of adolescent overweight and obesity. *Eur J Pediatr.* 2008;167(1):9-16. doi:10.1007/s00431-007-0575-z
10. Garg, Mayank, and Sandip Mohale. "Prevalence of Metabolic Obesity Normal Weight (MONW) in Cardiovascular Disease Patients - A Hospital-Based Case Control Study." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 34 (August 24, 2020): 2427–31. <https://doi.org/10.14260/jemds/2020/528>.
11. Hulkoti, Vidyashree S., Sourya Acharya, Samarth Shukla, Sree Karthik Partapa, and Yash Gupte. "In Search of an Ideal Obesity Assessment Tool: Is Body Mass Index Reliable Enough?" JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 35 (August 31, 2020): 2556–60. <https://doi.org/10.14260/jemds/2020/555>.

12. Rasheed, Aamil, Sourya Acharya, Samarth Shukla, Sunil Kumar, Roopesh Yarappa, Yash Gupte, and Vidyashree Hulkoti. "High-Sensitivity C-Reactive Protein in Metabolic Healthy Obesity (MHO)." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 7 (February 17, 2020): 443–47. <https://doi.org/10.14260/jemds/2020/100>.
13. Acharya, Sourya, and Samarth Shukla. "Metabolic Healthy Obesity-A Paradoxical Fallacy?" JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH 12, no. 10 (October 2018): OE7–10. <https://doi.org/10.7860/JCDR/2018/36809.12165>.
14. Parwe S, Mohan M, Bhagwat P, Nisargandha M. Effect of Rodhradi Gana Udavartana in the Management of Sthaulya (Overweight) with Special Reference to Obesity. INTERNATIONAL JOURNAL OF LIFE SCIENCE AND PHARMA RESEARCH. 2021 May;11(3):L30–7.
15. Bhonsle A, Parwe S, Nisargandha M. A Comparative Study to Evaluate the Efficacy of Lekhana Basti and Modified Vachadi Gana Basti in Combination with Navaka Guggulu in Sthaulya (Obesity) -A Study Protocol. JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL. 2021;33(30A):154–61.